# Juno Diagnostics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/juno-diagnostics

- Industry: Biotechnology
- Headquarters: San Diego, US
- Website: www.junodx.com
- Total disclosed funding: $25M
- Latest round: Series A (May 12, 2021)
- Investors on record: 5

## About

Juno Diagnostics, Inc. develops innovative diagnostic solutions, focusing on high-throughput genomic sequencing to enhance precision medicine. Their work facilitates rapid disease identification and personalized treatment strategies for healthcare professionals and researchers.Founded in 2017 in San Diego, US, Juno Diagnostics, Inc. specializes in genomic diagnostic solutions. The company has raised USD 25 mn in Series A funding led by Perceptive Advisors on May 12, 2021. The founders, Mathias Ehrich and Paul Oeth, have a history of involvement in the diagnostics industry, aiming to create impactful genomic technologies.Junodx specializes in advanced diagnostic solutions centered around high-throughput genomic sequencing technologies. Their offerings include platforms for genomic analysis that allow comprehensive genetic profiling, addressing challenges in personalized medicine such as rapid disease identification and tailored treatments. The company serves various clients, including academic institutions, healthcare providers, and pharmaceutical companies, focusing on markets in North America and Europe.Junodx generates revenue through direct sales and strategic partnerships, primarily engaging healthcare institutions and research organizations. Their transaction structure includes bulk purchase agreements for sequencing platforms with tiered pricing, along with subscription-based access to software tools for enhanced functionality. This approach ensures consistent revenue streams from both equipment sales and ongoing client relationships.Following the USD 25 mn Series A funding round in May 2021, Juno Diagnostics, Inc. plans to utilize these funds for clinical validation studies, product development, and the commercial launch of its noninvasive prenatal testing (NIPT) offerings. The company is focused on expanding its product portfolio and is targeting new markets in Europe and Asia by 2023, aiming to enhance its global reach in the genomic diagnostics field.

## Funding rounds

- Series A, May 12, 2021, $25M — Perceptive Advisors
- Seed, Jan 1, 2019 — Colle Capital, Prototype Capital, Zoic Capital, Saltagen Ventures

## Investors

- Colle Capital (https://capitalatlas.ai/funds/colle-capital) — Seed
- Prototype Capital — Seed
- Zoic Capital (https://capitalatlas.ai/funds/zoic-capital) — Seed
- Saltagen Ventures (https://capitalatlas.ai/funds/saltagen-ventures) — Seed
- Perceptive Advisors (https://capitalatlas.ai/funds/perceptive-advisors) — Series A